Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

Mise à jour : Il y a 4 ans
Référence : NCT02782858

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS). This study evaluates the effect on MRI lesions parameters, the safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis.


Critère d'inclusion

  • Multiple Sclerosis Relapsing Remitting

Liens